Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2002-08-30
2008-11-18
Campell, Bruce (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C530S326000, C424S093100
Reexamination Certificate
active
07452964
ABSTRACT:
The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 OR SEQ ID NO:144. The peptides may be attached to various therapeutic agents for targeted delivery. Adipose-targeting peptides may be used in methods for weight control, inducing weight loss and treating lipodystrophy syndrome. Adipose-targeting may also be accomplished using other binding moieties selectively targeted to adipose receptors, such as a prohibitin receptor protein complex. Placenta-targeting peptides may be used to interfere with pregnancy, induce labor and/or for targeted delivery of therapeutic agents to placenta and/or fetus. In other embodiments, receptors identified by binding to placenta-targeting peptides may be used to screen compounds for potential teratogenicity. An exemplary placental receptor is FcRn/β2M, and compounds that bind to FcRn/β2M are potential teratogens.
REFERENCES:
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4912040 (1990-03-01), Kaufman et al.
patent: 4931053 (1990-06-01), L'Esperance, Jr.
patent: 5021236 (1991-06-01), Gries et al.
patent: 5081034 (1992-01-01), Bevilasqua et al.
patent: 5098833 (1992-03-01), Lasky et al.
patent: 5188964 (1993-02-01), McGuire et al.
patent: 5206347 (1993-04-01), Ruoslahti et al.
patent: 5216131 (1993-06-01), Lasky et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5259380 (1993-11-01), Mendes et al.
patent: 5270163 (1993-12-01), Gold et al.
patent: 5288846 (1994-02-01), Quertermous et al.
patent: 5304640 (1994-04-01), Asky et al.
patent: 5415874 (1995-05-01), Bender et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5453362 (1995-09-01), Lamarco et al.
patent: 5463026 (1995-10-01), Nakamura et al.
patent: 5464436 (1995-11-01), Smith
patent: 5492807 (1996-02-01), Santi
patent: 5506126 (1996-04-01), Seed et al.
patent: 5536814 (1996-07-01), Ruoslahti et al.
patent: 5585277 (1996-12-01), Bowie et al.
patent: 5622699 (1997-04-01), Ruoslahti et al.
patent: 5670312 (1997-09-01), Santi
patent: 5688692 (1997-11-01), Jat et al.
patent: 5688935 (1997-11-01), Stephens et al.
patent: 5705610 (1998-01-01), Zuckerman et al.
patent: 5750344 (1998-05-01), Doyle
patent: 5840841 (1998-11-01), Zuckerman et al.
patent: 5866759 (1999-02-01), Jat et al.
patent: 5902598 (1999-05-01), Chen et al.
patent: 5955572 (1999-09-01), Ruoslahti et al.
patent: 6057098 (2000-05-01), Buechler et al.
patent: 6068829 (2000-05-01), Ruoslahti et al.
patent: 6174861 (2001-01-01), O'Reilly
patent: 6184973 (2001-02-01), Baer et al.
patent: 6215550 (2001-04-01), Baer et al.
patent: 6232440 (2001-05-01), Hillman et al.
patent: 6271196 (2001-08-01), O'Brien
patent: 6300064 (2001-10-01), Knappik et al.
patent: 6350855 (2002-02-01), Tobin
patent: 6399384 (2002-06-01), Jat
patent: 6458381 (2002-10-01), Sourovoi et al.
patent: 6528281 (2003-03-01), Tobin
patent: 6576239 (2003-06-01), Ruoslahti et al.
patent: 6881825 (2005-04-01), Robbins et al.
patent: 2001/0046498 (2001-11-01), Rouslahti et al.
patent: 2003/0113320 (2003-06-01), Ruoslahti et al.
patent: 2005/0191294 (2005-09-01), Arap et al.
patent: 19605175 (1997-08-01), None
patent: 0639584 (1998-04-01), None
patent: 4026631 (1992-01-01), None
patent: WO 92/00091 (1992-01-01), None
patent: WO 92/03461 (1992-03-01), None
patent: WO 92/06191 (1992-04-01), None
patent: WO 94/28424 (1994-12-01), None
patent: WO 95/14714 (1995-06-01), None
patent: WO 96/34874 (1996-11-01), None
patent: WO 96/34875 (1996-11-01), None
patent: WO 97/10507 (1997-03-01), None
patent: WO 97/19954 (1997-05-01), None
patent: WO 97/39021 (1997-10-01), None
patent: WO 98/10795 (1998-03-01), None
patent: WO 98/39469 (1998-09-01), None
patent: WO 99/04813 (1999-02-01), None
patent: WO 97/30024 (1999-09-01), None
patent: WO 99/46284 (1999-09-01), None
patent: WO 99/57311 (1999-11-01), None
patent: WO 00/14215 (2000-03-01), None
patent: WO 01/13114 (2001-02-01), None
patent: WO 01/42276 (2001-06-01), None
patent: WO 01/53342 (2001-07-01), None
patent: WO 02/02055 (2002-01-01), None
patent: WO 02/20722 (2002-03-01), None
patent: WO 02/20723 (2002-03-01), None
patent: WO 02/20769 (2002-03-01), None
patent: WO 02/20822 (2002-03-01), None
patent: WO 03/022991 (2003-03-01), None
Kolonin et al., “Targeting physiological and pathological blood vessel formation with in vivo phage display,”Proc. Am. Assoc. Cancer Res., 42:822-823, 2001.
St. Hilaire et al., “The Substrate specificity of a recombinant cystein protease fromLeishmania mexicana: application of a combinatorial peptide library approach,”Chembiochem: A European Journal of Chemical Biology, 1:115-122, 2000.
Alonso and Maroto, “Plants as ‘chemical factories’ for the production of polyunsaturated fatty acids,”Biotechnology Advances, 18:481-497, 200.
Arap et al., “Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands,”Cancer Cell, 6:275-284, 2004.
David et al., “Investigation of subsite preferences in aminopeptidase A (EC 3.4.11.7) led to the design of the first highly potent and selective inhibitors of this enzyme,”J. Med. Chem., 42:5197-5211, 1999.
De Rosa et al., “Poly(lactide-co-glycolide) microspheres for the controlled release of oligonucleotide/polyethylenimine complexes ,”J Pharm Sci, 91(3):790-799, 2002.
Fairbrother et al., “Novel Peptides Selected to Bind Vascular Endothelial Growth Factor Target Receptor-Binding Site,”Biochemistry, 37:17754-17764, 1998.
Georgiadis et al., “Potent and Selective Inhibition of Zinc Aminopeptidase A (EC 3.4.11.7, APA) by Glutamyl Aminophosphinic Peptides: Importance of Glutamyl Aminophosphinic Residue in the P1 Position,”Biochemistry, 39:1152-1155, 2000.
Gong et al., “Prostrate-specific membrane antigen (PMSA)-specific monoclonal antibodies in the treatment of prostrate and other cancers,”Cancer and Metastasis Reviews, 18:483-490, 1999.
Johnson et al., In:Biotechnology and Pharmacy, Pezzuto et al. eds., Chapman and Hall, NY, 1993.
Kolonin et al., “Reversal of obesity by targeted ablation of adipose tissue,”Nature Medicine, 10: 625-632, 2004.
Mintz et al., “Fingerprinting the circulating repertoire of antibodies from cancer patients,”Nature Biotechnology, 21:57-63, 2003.
Napier and Michaelson, “Genomic and Functional Characterization of Polyunsaturated Fatty Acid Biosynthesis inCaenorhabditis elegans,”Lipids, 36:761-766, 2001.
Nicklin et al., “Selective argeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display,”Circulation, 102:231-237, 2000.
Oike et al., “Angiopoietin-related growth factors antagonizes obesity and insulin resistence,”Nature Medicine, 11:400-408, 2005.
Ozata et al., “Human Leptin Deficiency caused by a missense Mutation: Multiple Endocrine Defects, Decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater centralthan peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defec,”Jounral of Clinical Endocrinology and Metabolism, 84:3686-3695, 1999.
Polgren et al., “Identification of muscle homing sequences by using phage display libraries of peptides,”Tumor Biology, 18:77, 1997.
Quirk et al., “Amastatin and bestatin-induced dipsogenicity in the Sprague-Dawley rat,”Brain Res. Bull., 19:145-147, 1987.
Schindler, “Select, microdissect, adneject.”Nature Biotechnology, 16:719-720,1998.
Wang et al., “Rapid antibody responses by low-dose, single-step, dendritic cell-target immunization,”Proceedings of the National Academy of Sciences of the United States of America, 97:847-852, 2000.
Yao et al. “Targeting pancreatic islets with phage display assisted by las
Arap Wadih
Kolonin Mikhail G.
Pasqualini Renata
Board of Regents the University of Texas System
Campell Bruce
Fulbright & Jaworski L.L.P.
Li Bao Qun
LandOfFree
Compositions and methods of use of targeting peptides... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods of use of targeting peptides..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods of use of targeting peptides... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4044102